<DOC>
	<DOCNO>NCT02462031</DOCNO>
	<brief_summary>To Evaluate safety , tolerability pharmacokinetic property KD101 multiple oral dosing fed state obese overweight subject .</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability , PK , PK-PD Relation KD101 Fed State Obese Overweight Subjects</brief_title>
	<detailed_description>dose block-randomized , double-blinded , placebo control , single multiple ascend dose study . AEs , PE , Vital sign , ECGs Clinical lab test - Part I : multiple dose study ( KD101 placebo ) / male female - Part II : single dose study ( KD101 ) / male</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>Male Female adult age 20 55 screening ( Part II : Male adult age 20 55 screening ) Healthy volunteer whose BMI ≥ 27 ( Part II : Healthy volunteer whose BMI ≥ 18 ) Female pregnancy possibility Male/Female abstinence contraception clinical trial Subjects clinically significant disease history ( liver , kidney , nervous , pulmonary , endocrinal , urinary , cardiovascular , musculoskeletal , mental system , blood , tumor ) diagnose within 1 month screen Subjects gastrointestinal disease ( Crohn 's disease , ulcer , acute/chronic pancreatitis ) affect absorption test drug gastrointestinal operation ( However , appendectomy , herniotomy induce acute appendicitis exclude ) Subjects follow history . [ myocardial infarction ( diagnosed cardiac enzyme and/or diagnostic ECG ) , cerebral infarction/stroke , arrhythmia need medical treatment , unstable angina , pulmonary hypertension ] Subjects positive result Human Immunodeficiency Virus , Hepatitis B virus , Hepatitis C virus screen Subjects allergy history ( ex . allergy aspirin , antibiotic , etc ) clinicallysignificant allergy Subjects whose systolic BP &lt; 85mmHg &gt; 145mmHg , diastolic BP &lt; 50mmHg &gt; 95mmHg , pulse &gt; 100/min 3 minuteseating position . ( BP remeasured twice leat 5 minuteinterval ) Subjects would take prescribed/oriental drug ( within 2 week first dose day ) OTC drug vitamines ( within 1 week first dose day ) Subjects drink 21 unit ( 1 unit = 10g pure alcohol ) quit drink alcohol clinical trial period Subjects ate follow food within 2 day first dose day quit follow food [ grapefruitcontain food , caffeincontain food ( coffee , green tea , black tea , soft drink , coffee milk , energy drink ) ] Subjects n't agree contraception Subjects n't agree quit smoke Subjects donate his/her blood within 2 month ( whole blood ) / 1 month ( apheresis ) take transfusion within 1 month Subjects participate another clinical trial within 3 month first dose day . ( The clinical trial completion day define last dosing day past clinical trial ) Subjects adequate trial lab examination another reason Subjects weigh loss 5kg 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>